<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">MSCE</journal-id><journal-title-group><journal-title>Journal of Materials Science and Chemical Engineering</journal-title></journal-title-group><issn pub-type="epub">2327-6045</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/msce.2015.36002</article-id><article-id pub-id-type="publisher-id">MSCE-57051</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Chemistry&amp;Materials Science</subject></subj-group></article-categories><title-group><article-title>
 
 
  Synthesis of (2S,4S)-2-Substituted-3- (3-Sulfanylpropanoyl)-6- Oxohexahydropyrimidine-4-Carboxylic Acids as Potential Antihypertensive Drugs
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Andrei</surname><given-names>Ershov</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dmitry</surname><given-names>Nasledov</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Igor</surname><given-names>Lagoda</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Valery</surname><given-names>Shamanin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Institute of Macromolecular Compouns of Russian Academy of Sciences, Saint Petesburg, Russia</addr-line></aff><pub-date pub-type="epub"><day>11</day><month>06</month><year>2015</year></pub-date><volume>03</volume><issue>06</issue><fpage>7</fpage><lpage>12</lpage><history><date date-type="received"><day>January</day>	<month>2015</month>	</date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   Proceeding from natural amino acid L-asparagine and commercially available aldehydes a stereoselective synthesis was developed of (2S,4S)-2-alkyl(aryl)-3-(3-sulfanylpropanoyl)-6-oxohexahy- dropyrimidine-4-carboxylic acids, potential antihypertensive drugs, inhibitors of the angiotensin converting enzyme. 
 
</p></abstract><kwd-group><kwd>Synthesis of (2S</kwd><kwd>4S)-2-Substituted-3- (3-Sulfanylpropanoyl)-6- Oxohexahydropyrimidine-4-Carboxylic  Acids as Potential Antihypertensive Drugs</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Efficient antihypertensive drugs function as inhibitors of the angiotensin converting enzyme (ACE). This enzyme is involved in the regulator system rennin-angiotensin-aldosterone, and the distortion of its operation results in the majority of hypertensive human diseases [<xref ref-type="bibr" rid="scirp.57051-ref1">1</xref>]-[<xref ref-type="bibr" rid="scirp.57051-ref3">3</xref>]. The first of the drugs from this series was captopril, (S)-N-(3-sulfanyl-2-methyl-1-oxopropyl)-L-proline [<xref ref-type="bibr" rid="scirp.57051-ref4">4</xref>]. The later research on development of antihypertensive substances, ACE inhibitors, was directed to the replacement of the natural amino acid L-proline in the captopril molecule by synthetic cyclic amino acids of the heterocyclic series, among them derivatives of 1,3-oxazolidine [<xref ref-type="bibr" rid="scirp.57051-ref5">5</xref>], 1,3-thiazolidine [<xref ref-type="bibr" rid="scirp.57051-ref6">6</xref>], pipecoline [<xref ref-type="bibr" rid="scirp.57051-ref7">7</xref>], quinazoline [<xref ref-type="bibr" rid="scirp.57051-ref8">8</xref>], indole [<xref ref-type="bibr" rid="scirp.57051-ref9">9</xref>], and azepine [<xref ref-type="bibr" rid="scirp.57051-ref10">10</xref>]. In the series of the saturated pyrimidine derivatives the only example of the inhibitor activity with respect to ACE is known to be shown by 3-(3-sulfanylpropanoyl)-6-oxohexahydropyrimidine-4-carboxylic acid [<xref ref-type="bibr" rid="scirp.57051-ref11">11</xref>].</p><p>It was found by the analysis of published data that sodium (potassium) salts of 2-substituted 6-oxohexahydro&#173;pyrimidine-4-carboxylic acids formed in the reaction of the natural amino acid L-asparagine with carbonyl compounds in alkaline medium. This reaction was investigated mainly by an example of derivatives of isobutyric, trimethylacetic, and benzoic aldehydes [<xref ref-type="bibr" rid="scirp.57051-ref12">12</xref>]-[<xref ref-type="bibr" rid="scirp.57051-ref16">16</xref>]. The process was found to occur with a high stereoselectivity giving prevailingly the spatial isomer with (2R,4S)-configuration of the substituents in the pyrimidine ring.</p><p>The derivatives of 6-oxohexahydropyrimidine-4-carboxylic acids are used as key intermediates in the synthesis of β-amino acids [<xref ref-type="bibr" rid="scirp.57051-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.57051-ref13">13</xref>], in the asymmetric cycloaddition reactions [<xref ref-type="bibr" rid="scirp.57051-ref14">14</xref>], in liposomal microencapsulation of biopreparations [<xref ref-type="bibr" rid="scirp.57051-ref15">15</xref>].</p></sec><sec id="s2"><title>2. Results and Discussion</title><p>The goal of this study is the search for new and synthetically accessible potential antihypertensive substances, ACE inhibitors, compounds where the cyclic amino acid fragment is a derivative of pyrimidine-4-carboxylic acid.</p><p>Compounds 2а-i were obtained in 70% - 90% yields after maintaining L-asparagine, an appropriate aliphatic or aromatic aldehyde, and equivalent quantity of sodium hydroxide in methanol solution for 10 - 12 h at 25˚С (see Scheme 1 and <xref ref-type="table" rid="table1">Table 1</xref>).</p><p>The first objects of our investigation were the condensation products of L-asparagine with a series of aliphatic aldehydes, compounds 2а-f. The cyclic pyrimidine structure of these compounds is unquestionable, as shows the appearance in the <sup>1</sup>Н NMR spectra of the typical АВХ system due to the diastereotopic character of Н-5 and Н-4 protons, of the signals of Н-2 atom in the region 4.2 - 4.5 ppm, and in the <sup>13</sup>С NMR spectra, of the signal of sp<sup>3</sup>- hybridized С-2 atom in the region 65 - 70 ppm. In the spectra of all obtained compounds 2а-f two sets of resonance signals from (2R,4S)-and (2S,4S)-stereoisomeric forms of the pyrimidine ring are observed. The assign- ment of the stereoisomeric forms of compounds 2а-f is based on the formerly established criteria and rules ob-</p><disp-formula id="scirp.57051-formula326"><graphic  xlink:href="http://html.scirp.org/file/57051x4.png"  xlink:type="simple"/></disp-formula><p>Scheme 1. i: RCH=O, NaOH/MeOH, 25˚C, 10 - 12 h. R = Me (a), Et (b), Bu (c), i-Pr (d), i-Bu (e), CH<sub>2</sub>CH<sub>2</sub>Ph (f), R =XC<sub>6</sub>H<sub>4</sub>, X = H (g), 4-Cl (h), 4-MeO (i).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics of compounds 2a-i</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Compound</th><th align="center" valign="middle"  rowspan="2"  >[α]<sub>D</sub><sup>25</sup> in MeOH</th><th align="center" valign="middle"  colspan="3"  >Tautomeric composition in D<sub>2</sub>O, (%)</th></tr></thead><tr><td align="center" valign="middle" >Form A</td><td align="center" valign="middle" >Form (2R,4S)</td><td align="center" valign="middle" >Form (2S,4S)</td></tr><tr><td align="center" valign="middle" >2a</td><td align="center" valign="middle" >?89.1, с 1.31</td><td align="center" valign="middle" >?</td><td align="center" valign="middle" >95</td><td align="center" valign="middle" >5</td></tr><tr><td align="center" valign="middle" >2b</td><td align="center" valign="middle" >?91.2, с 1.50</td><td align="center" valign="middle" >?</td><td align="center" valign="middle" >93</td><td align="center" valign="middle" >7</td></tr><tr><td align="center" valign="middle" >2c</td><td align="center" valign="middle" >?70.1, с 1.50</td><td align="center" valign="middle" >?</td><td align="center" valign="middle" >90</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle" >2d</td><td align="center" valign="middle" >?97.7, с 1.40</td><td align="center" valign="middle" >?</td><td align="center" valign="middle" >93</td><td align="center" valign="middle" >7</td></tr><tr><td align="center" valign="middle" >2e</td><td align="center" valign="middle" >?77.2, с 1.53</td><td align="center" valign="middle" >?</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >13</td></tr><tr><td align="center" valign="middle" >2f</td><td align="center" valign="middle" >?69.5, с 1.50</td><td align="center" valign="middle" >?</td><td align="center" valign="middle" >92</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >2g</td><td align="center" valign="middle" >?60.2, с 2.01</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >19</td></tr><tr><td align="center" valign="middle" >2h</td><td align="center" valign="middle" >?35.1, с 2.02</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >9</td></tr><tr><td align="center" valign="middle" >2i</td><td align="center" valign="middle" >?37.2, с 1.70</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >16</td></tr></tbody></table></table-wrap><p>tained at the use of <sup>1</sup>Н and <sup>13</sup>С NMR spectroscopy [<xref ref-type="bibr" rid="scirp.57051-ref13">13</xref>]-[<xref ref-type="bibr" rid="scirp.57051-ref15">15</xref>], and also on the data of X-ray diffraction analysis [<xref ref-type="bibr" rid="scirp.57051-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.57051-ref16">16</xref>]. In keeping with the comparison of the <sup>1</sup>Н and <sup>13</sup>С NMR spectra of compounds 2а-f to the analogous spectral characteristics published in [<xref ref-type="bibr" rid="scirp.57051-ref13">13</xref>]-[<xref ref-type="bibr" rid="scirp.57051-ref16">16</xref>] the (2R,4S)-configuration was assigned to the main isomer. In the <sup>1</sup>Н NMR spectrum of this stereoisomer the protons Н-5 and Н-4 are characterized by larger spin-spin coupling constant (J<sub>AВ</sub> = 17 Hz, J<sub>AX</sub> + J<sub>BX</sub> = 16 Hz), and the signals of Н-5 and Н-4 protons are considerably shifted upfield than the analogous signals of the stereoisomer with (2S,4S)-configuration. The corresponding coupling constant in the latter isomer is smaller (J<sub>AВ</sub> = 15 Hz, J<sub>AX</sub> + J<sub>BX</sub> = 13 Hz).</p><p>The position of the configurational equilibrium of compounds 2а-f is shifted to a large extent to (2R,4S)-ste- reoisomer, therefore it is impossible to obtain a clear correlation between the logarithms of the constant of the configurational equilibrium and the Taft steric constants of alkyl substituents. The largest fraction of the minor (2S,4S)-isomer (13%) was observed in the D<sub>2</sub>O solution of compound 2e, isovaleric aldehyde derivative.</p><p>In the <sup>1</sup>Н and <sup>13</sup>С NMR spectra in D<sub>2</sub>O of the L-asparagine condensation products with aromatic aldehydes (compounds 2g-i) alongside the signals of two configuration isomers of the pyrimidine form signals appear of a linear form А. Not entering into details of the previously found by us [<xref ref-type="bibr" rid="scirp.57051-ref17">17</xref>] spectral distinctions between the cyclic and linear forms of compounds 2g-i we only mention that the typical signs of the latter in the <sup>1</sup>Н NMR spectrum is a significant downfield shift of the protons of СН<sub>2</sub>СН group as compared with analogous signals Н-5 and Н-4 of cyclic forms, the appearance of the proton signal of the azomethine group at 8.25 - 8.35 ppm, and in the <sup>13</sup>С NMR spectrum, of the downfield signal at 165 ppm (C=N).</p><p>By an example of compound 2g, the condensation product of L-asparagine with benzaldehyde, we studied the dependence of the position of the tautomeric equilibrium on the nature of the applied solvent (see <xref ref-type="table" rid="table2">Table 2</xref>). In the crystalline state compound 2g exists in the cyclic pyrimidine (2R,4S)-form as confirmed by the solid state <sup>13</sup>С NMR spectrum [<xref ref-type="bibr" rid="scirp.57051-ref17">17</xref>]. In all solvents the coexistence of tautomeric forms was observed, and in going to aprotic polar solvents (DMSO-D<sub>6</sub> and DMF-D<sub>7</sub>) the fraction of the linear form A significantly increased.</p><p>Hence the products of L-asparagine condensation with acetic, propionic, valeric, isobutyric, isovaleric, and hydrocinnamic aldehydes in alkaline medium have the cyclic pyrimidine structure, and in D<sub>2</sub>O solutions they are present as two cyclic spatial stereoisomers with a significant prevalence of the (2R,4S)-form. In neither case the appearance in the solutions of the linear imine form А was observed. In this respect compounds 2а-f fundamentally differ from the condensation products of L-asparagine with a series of aromatic aldehydes 2g-i where the occurrence of the ring-chain tautomerism has been found and alongside two pyrimidine stereoisomers a linear form exists in solutions.</p><p>The acylation of 2-substituted 6-oxohexahydropyrimidine-4-carboxylic acids results in the formation of optically pure N-acyl derivatives with (2S,4S)-configuration of the substituents at the pyrimidine ring [<xref ref-type="bibr" rid="scirp.57051-ref13">13</xref>]-[<xref ref-type="bibr" rid="scirp.57051-ref16">16</xref>]. In some studies the ability was demonstrated of (2S,4S)-3-acyl-2-substituted-6-oxohexahydropyrimidine-4-carbo&#173;xylic acids to the conformational cis,trans-isomerization in solutions due to effect of the hindered rotation relative to C?N bond of the amide fragment [<xref ref-type="bibr" rid="scirp.57051-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.57051-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.57051-ref18">18</xref>].</p><p>It was found that acylation of compounds 2а-i with 3-(acetylthio)propionyl chloride proceeded in acetone and completed in 10-12 h with the formation of 3-(3-acetylsulfanylpropanoyl)-2-alkyl(aryl)-6-oxohexahydropyrimi&#173;dine-4-carboxylic acids 3а-i (see Scheme 2 and <xref ref-type="table" rid="table3">Table 3</xref>).</p><p>The acylation products 3а-i possess the (2S,4S)-configuration of the substituents of the pyrimidine ring, in their solutions in DMSO-D<sub>6</sub>, in keeping with the data of <sup>1</sup>Н and <sup>13</sup>С NMR spectra, the presence of two cis, trans- conformers has been found in the ratio ~3:2. It was confirmed by the coalescence of doubled signals at the re-</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Tautomeric composition (%) of compound 2g in various solvents 48 h after dissolution</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Solvent</th><th align="center" valign="middle" >Form A</th><th align="center" valign="middle" >Form (2R,4S)</th><th align="center" valign="middle" >Form (2S,4S)</th></tr></thead><tr><td align="center" valign="middle" >Solid phase</td><td align="center" valign="middle" >?</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >?</td></tr><tr><td align="center" valign="middle" >D<sub>2</sub>O</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >19</td></tr><tr><td align="center" valign="middle" >Pyridine-D<sub>5</sub></td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >12</td></tr><tr><td align="center" valign="middle" >DMSO-D<sub>6</sub></td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >DMF-D<sub>7</sub></td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >9</td></tr></tbody></table></table-wrap><disp-formula id="scirp.57051-formula327"><graphic  xlink:href="http://html.scirp.org/file/57051x5.png"  xlink:type="simple"/></disp-formula><p>Scheme 2. ii: AcSCH<sub>2</sub>CH<sub>2</sub>COCl/Me<sub>2</sub>CO, C<sub>5</sub>H<sub>5</sub>N, 5˚C - 10˚C, 10 - 12 h. R = Me (a), Et (b), Bu (c), i-Pr (d), i-Bu (e), CH<sub>2</sub>CH<sub>2</sub>Ph (f), R =XC<sub>6</sub>H<sub>4</sub>, X = H (g), 4-Cl (h), 4-MeO (i).</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Characteristics of compounds 3a-i</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Compound</th><th align="center" valign="middle" >[α]<sub>D</sub><sup>25</sup> in DMF</th><th align="center" valign="middle" >mp, ˚C</th><th align="center" valign="middle" >Yield, %</th></tr></thead><tr><td align="center" valign="middle" >3a</td><td align="center" valign="middle" >?52.1, c 1.00</td><td align="center" valign="middle" >73 - 75</td><td align="center" valign="middle" >45</td></tr><tr><td align="center" valign="middle" >3b</td><td align="center" valign="middle" >?87.2, c 1.20</td><td align="center" valign="middle" >121 - 123</td><td align="center" valign="middle" >52</td></tr><tr><td align="center" valign="middle" >3c</td><td align="center" valign="middle" >?115.8, c 1.10</td><td align="center" valign="middle" >92 - 94</td><td align="center" valign="middle" >56</td></tr><tr><td align="center" valign="middle" >3d</td><td align="center" valign="middle" >?114.8, c 1.10</td><td align="center" valign="middle" >133 - 135</td><td align="center" valign="middle" >65</td></tr><tr><td align="center" valign="middle" >3e</td><td align="center" valign="middle" >?109.4, c 1.15</td><td align="center" valign="middle" >119 - 121</td><td align="center" valign="middle" >65</td></tr><tr><td align="center" valign="middle" >3f</td><td align="center" valign="middle" >?57.4, c 1.10</td><td align="center" valign="middle" >125 - 127</td><td align="center" valign="middle" >68</td></tr><tr><td align="center" valign="middle" >3g</td><td align="center" valign="middle" >+52.1, c 1.00</td><td align="center" valign="middle" >88 - 91</td><td align="center" valign="middle" >53</td></tr><tr><td align="center" valign="middle" >3h</td><td align="center" valign="middle" >+19.4, c 1.10</td><td align="center" valign="middle" >93 - 95</td><td align="center" valign="middle" >56</td></tr><tr><td align="center" valign="middle" >3i</td><td align="center" valign="middle" >+35.1, c 1.20</td><td align="center" valign="middle" >78 - 81</td><td align="center" valign="middle" >62</td></tr></tbody></table></table-wrap><p>gistering <sup>1</sup>Н NMR spectra in DMSO-D<sub>6</sub> at higher temperature (~80˚С - 85˚С). Proceeding from the comparison of the <sup>1</sup>Н and <sup>13</sup>С NMR spectra of compounds 3а-i with the published [<xref ref-type="bibr" rid="scirp.57051-ref13">13</xref>]-[<xref ref-type="bibr" rid="scirp.57051-ref16">16</xref>] spectral characteristics of 3-alkanoyl-2-substituted 6-oxohexahydropyrimidine-4-carboxylic acids the trans-configuration was ascribed to the main isomer. This conformer is characterized by the downfield shift of Н-4 and Н-2 signals in the <sup>1</sup>Н NMR spectrum compared the analogous signals of the minor cis-isomer. The position of the conformational equilibrium is governed by the nature of the applied solvent, and in going from СDCl<sub>3</sub> to polar solvents, as show the data for compounds 3а-i, the stability of the more polar cis-conformer increases.</p><p>The removal of S-acetyl protection in compounds 3а-i occurs in the ammonia solution within several hours at room temperature and leads to the formation of (2S,4S)-2-alkyl(aryl)-3-sulfanylpropanoyl-6-oxohexahydropyri&#173;midine-4-carboxylic acids 4а-i in 50% - 65% yields (see Scheme 3 and <xref ref-type="table" rid="table4">Table 4</xref>). In the <sup>1</sup>Н NMR spectra in DMSO-D<sub>6</sub> of compounds 4а-i a triplet signal is observed from the proton of the SH group in the region 1.45 - 2.10 ppm. Like in compounds 3а-i, in the solutions of products 4а-i cis- and trans-conformers are present due to the effect of the hindered amide rotation.</p></sec><sec id="s3"><title>3. Experimental</title><p><sup>1</sup>Н and <sup>13</sup>С NMR spectra were registered on a spectrometer Bruker AV-400 at operating frequencies 400 and 100 MHz respectively (internal reference HMDS). The stereoisomeric composition of obtained compounds was estimated by the integration of the appropriate signals in the <sup>1</sup>Н NMR spectra. The specific optical rotation was measured on a polarimeter P-161M at the wavelength of the plane-polarized light 589 nm. Elemental analysis of newly obtained compounds was carried out on a CHN Analyzer Hewlett Packard 185B. The purity of prepared compounds was checked by TLC on Silufol UV-254 plates, eluent benzene-acetone, 1:1.</p><p>Compounds 2а-i are white or light yellow amorphous hygroscopic powders, mp &gt;250˚С. Spectral characteristics of compounds 2a-i, 3a-i, and 4a-i were described previously [<xref ref-type="bibr" rid="scirp.57051-ref19">19</xref>]. 3-(Acetylsulfanyl)propanoyl chloride was obtained by the method [<xref ref-type="bibr" rid="scirp.57051-ref20">20</xref>].</p></sec><sec id="s4"><title>4. Conclusions</title><p>Hence we developed a three-stage stereoselective synthesis from L-asparagine of previously unknown (2S,4S)-</p><disp-formula id="scirp.57051-formula328"><graphic  xlink:href="http://html.scirp.org/file/57051x6.png"  xlink:type="simple"/></disp-formula><p>Scheme 3. iii: NH<sub>3</sub>(aq.), 25˚C, 5 - 10 h. R = Me (a), Et (b), Bu (c), i-Pr (d), i-Bu (e), CH<sub>2</sub>CH<sub>2</sub>Ph (f), R = XC<sub>6</sub>H<sub>4</sub>, X = H (g), 4-Cl (h), 4-MeO (i).</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Characteristics of compounds 4a-i</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Compound</th><th align="center" valign="middle" >[α]<sub>D</sub><sup>25</sup> in MeOH</th><th align="center" valign="middle" >mp., ˚C</th><th align="center" valign="middle" >Yield, %</th></tr></thead><tr><td align="center" valign="middle" >4a</td><td align="center" valign="middle" >?48.6, c 1.30</td><td align="center" valign="middle" >189 - 191</td><td align="center" valign="middle" >66</td></tr><tr><td align="center" valign="middle" >4b</td><td align="center" valign="middle" >?76.5, c 1.37</td><td align="center" valign="middle" >165 - 168</td><td align="center" valign="middle" >58</td></tr><tr><td align="center" valign="middle" >4c</td><td align="center" valign="middle" >?84.2, c 1.15</td><td align="center" valign="middle" >122 - 125</td><td align="center" valign="middle" >50</td></tr><tr><td align="center" valign="middle" >4d</td><td align="center" valign="middle" >?95.7, c 1.10</td><td align="center" valign="middle" >184 - 186</td><td align="center" valign="middle" >65</td></tr><tr><td align="center" valign="middle" >4e</td><td align="center" valign="middle" >?122.8, c 1.20</td><td align="center" valign="middle" >162 - 164</td><td align="center" valign="middle" >60</td></tr><tr><td align="center" valign="middle" >4f</td><td align="center" valign="middle" >?80.1, c 1.00</td><td align="center" valign="middle" >132 - 134</td><td align="center" valign="middle" >54</td></tr><tr><td align="center" valign="middle" >4g</td><td align="center" valign="middle" >+13.7, c 1.00</td><td align="center" valign="middle" >120 - 123</td><td align="center" valign="middle" >55</td></tr><tr><td align="center" valign="middle" >4h</td><td align="center" valign="middle" >+22.4, c 1.00</td><td align="center" valign="middle" >202 - 204</td><td align="center" valign="middle" >58</td></tr><tr><td align="center" valign="middle" >4i</td><td align="center" valign="middle" >+28.7, c 1.10</td><td align="center" valign="middle" >148 - 151</td><td align="center" valign="middle" >65</td></tr></tbody></table></table-wrap><p>3-(3-sulfanylpropanoyl)-2-alkyl(aryl)-6-oxohexahydropyrimidine-4-carboxylic acids 4а-i, potential antihypertensive drugs, ACE inhibitors [<xref ref-type="bibr" rid="scirp.57051-ref21">21</xref>]; the compounds otained are structural analogs of the known antihypertensive drug methiapril, (2S,6S)-1-[(3-acetylsulfanyl)propanoyl]-6-methylpipecolinic acid [<xref ref-type="bibr" rid="scirp.57051-ref7">7</xref>]. However unlike methiapril whose production requires difficultly available synthetic (2S,6S)-6-methylpipecolinic acid [<xref ref-type="bibr" rid="scirp.57051-ref22">22</xref>], the stereoselective synthesis of compounds 4а-i is underlain by natural or commercially available reagents. Besides, by varying the structure of the initial aldehyde component the developed procedure makes it possible to introduce in the position 2 of pyrimidine ring substituents of diverse nature, length, and branching.</p></sec><sec id="s5"><title>Acknowledgements</title><p>This work received financial support from the Ministry of Education and Science of the Russian Federation (contract 14.547.21.0002, no. RFMEFI57414X0002).</p></sec><sec id="s6"><title>Cite this paper</title><p>Andrei Ershov,Dmitry Nasledov,Igor Lagoda,Valery Shamanin, (2015) Synthesis of (2S,4S)-2-Substituted-3- (3-Sulfanylpropanoyl)-6- Oxohexahydropyrimidine-4-Carboxylic Acids as Potential Antihypertensive Drugs. Journal of Materials Science and Chemical Engineering,03,7-12. doi: 10.4236/msce.2015.36002</p></sec><sec id="s7"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.57051-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Wyvratt, M.J. and Patchett, A.A. (1985) Medicinal Research Reviews, 5, 483-531.  
http://dx.doi.org/10.1002/med.2610050405</mixed-citation></ref><ref id="scirp.57051-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Brown, N.J. and Vaughan, D.E. (1998) Circulation, 97, 1411-1420. http://dx.doi.org/10.1161/01.CIR.97.14.1411</mixed-citation></ref><ref id="scirp.57051-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ondetti, M.A., Rubin, B. and Cushman, D.W. (1977) Science, 196, 441-444. http://dx.doi.org/10.1126/science.191908</mixed-citation></ref><ref id="scirp.57051-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ondetti, M.A. and Cushman, D.W. (1978) US Patent No. 4105776.</mixed-citation></ref><ref id="scirp.57051-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ryono, D.E. and Ondetti, M.A. (1982) US Patent No. 4321392.</mixed-citation></ref><ref id="scirp.57051-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ondetti, M.A. (1981) US Patent No. 4282235.</mixed-citation></ref><ref id="scirp.57051-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Yakhontov, L.N., Mashkovskij, M.D., Kugaevskaya, E.V., Orekhovich, V.N., Pavlikhina, L.V., Eliseeva, Y.E., Mastafanova, L.I., Evstratova, M.I. and Shvarts, G.Y. (1993) SU Patent No. 1838298.</mixed-citation></ref><ref id="scirp.57051-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Nozawa, K., Yoshizawa, T. and Kuroda, N. (1985) US Patent No. 4537967.</mixed-citation></ref><ref id="scirp.57051-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Stanton, J.L. and Gruenfeld, N. (1986) UA Patent No. 4599357.</mixed-citation></ref><ref id="scirp.57051-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Robl, J.A. (1999) US Patent No. 5856476.</mixed-citation></ref><ref id="scirp.57051-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Nakamura, S., Tsuda, Y. and Doi, T. (1983) JP Patent No. 58110573.</mixed-citation></ref><ref id="scirp.57051-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Juaristi, E., Lopez-Ruiz, H., Madrigal, D., Ramirez-Quiros, Y. and Escalante, J. (1998) Journal of Organic Chemistry, 63, 4706-4710. http://dx.doi.org/10.1021/jo980367a</mixed-citation></ref><ref id="scirp.57051-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Juaristi, E., Quintana, D., Balderas, M. and Gareia-Perez, E. (1996) Tetrahedron: Asymmetry, 7, 2233-2246.   
http://dx.doi.org/10.1016/0957-4166(96)00278-9</mixed-citation></ref><ref id="scirp.57051-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Lakner, F.J. and Negrete, G.R. (2002) Synlett, 643-645. http://dx.doi.org/10.1055/s-2002-22712</mixed-citation></ref><ref id="scirp.57051-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Mfuh, A.M., Mahindaratne, M.P.D., Quintero, M.V., Lakner, F.J., Bao, A., Goins, B.A., Phillips, W.T. and Negrete, G.R. (2011) Langmuir, 27, 4447-4455. http://dx.doi.org/10.1021/la105085k</mixed-citation></ref><ref id="scirp.57051-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kundu, S.K., Mahindaratne, M.P.D., Quinones, B., Negrete, G.R. and Tiekink, E.R.T. (2010) Acta Crystallographica, E66, o3.</mixed-citation></ref><ref id="scirp.57051-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Ershov, A.Yu., Nasledov, D.G., Nasonova, K.V., Sezyavina, K.V., Susarova, T.V., Lagoda, I.V. and Shamanin, V.V. (2013) Chemistry of Heterocyclic Compounds, 49, 598-603. http://dx.doi.org/10.1007/s10593-013-1287-0</mixed-citation></ref><ref id="scirp.57051-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Negrete, G.R., Mahindaratne, M.P.D., Mfuh, A.M. and Quintero, M.V. (2011) US Patent No. 20110268653.</mixed-citation></ref><ref id="scirp.57051-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ershov, A.Yu., Nasledov, D.G., Parilova, E.V., Lagoda, I.V. and Shamanin, V.V. (2013) Russian Journal of Organic Chemistry, 50, 1164-1174. http://dx.doi.org/10.1134/S1070428014080168</mixed-citation></ref><ref id="scirp.57051-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Daeniker, H.U. and Druey, J. (1957) Helvetica Chimica Acta, 40, 2148-2156.  
http://dx.doi.org/10.1002/hlca.19570400714</mixed-citation></ref><ref id="scirp.57051-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ershov, A.Yu., Susarova, T.V., Chernitsa, B.V. and Shamanin, V.V. (2011) RF Patent No. 245528.</mixed-citation></ref><ref id="scirp.57051-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kadouri-Puchot, C. and Comesse, S. (2005) Amino Acids, 29, 101-130. http://dx.doi.org/10.1007/s00726-005-0193-x</mixed-citation></ref></ref-list></back></article>